U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Ceftazidime – Injection products
  1. Development Resources

Ceftazidime – Injection products

Recognized Interpretive Criteria

Exceptions to the recognized standard of CLSI M100

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacterales

M100 standard is recognized

Pseudomonas aeruginosa a

≤ 8

-

≥ 16

≥ 18

-

≤ 17

Acinetobacter spp.

M100 standard is recognized

-

-

-

Burkholderia cepacia
complex

M100 standard is recognized

-

-

-

Haemophilus influenzae and
parainfluenzae

M100 standard is recognized

S = Susceptible; I = Intermediate; R = Resistant
a For P. aeruginosa, susceptibility interpretive criteria are based on a dose of 2 grams IV every 8 hours in patients with normal renal function

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp. disk diffusion interpretive criteria (Interpretive criteria for MIC are recognized.)

Other Non-Enterobacterales

Back to Top